Context Therapeutics Inc
NASDAQ:CNTX
Context Therapeutics Inc
Research & Development
Context Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Context Therapeutics Inc
NASDAQ:CNTX
|
Research & Development
-$22.7m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Context Therapeutics Inc
Glance View
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-10-20. The firm is engaged in developing small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company’s clinical program for lead candidate, onapristone extended release (ONA-XR), comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Its second program, CLDN6xCD3, is an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing Claudin 6 (CLDN6).
See Also
What is Context Therapeutics Inc's Research & Development?
Research & Development
-22.7m
USD
Based on the financial report for Dec 31, 2024, Context Therapeutics Inc's Research & Development amounts to -22.7m USD.
What is Context Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-57%
Over the last year, the Research & Development growth was -28%. The average annual Research & Development growth rates for Context Therapeutics Inc have been -49% over the past three years , -57% over the past five years .
